Cargando…

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland.

The possibility of screening the general population for prostate cancer using serum prostate-specific antigen (PSA) level (alone or in combination with other tests) as screening test has recently been discussed. A number of studies are on the way, but the published reports have almost exclusively be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auvinen, A., Tammela, T., Stenman, U. H., Uusi-Erkkilä, I., Leinonen, J., Schröder, F. H., Hakama, M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074672/ https://www.ncbi.nlm.nih.gov/pubmed/8761371

Ejemplares similares

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

European randomized study of prostate cancer screening: first-year results of the Finnish trial
por: Määttänen, L, et al.
Publicado: (1999)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

Outcomes of prostate cancer screening among men using antidiabetic medication
por: Vettenranta, A., et al.
Publicado: (2021)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Chernobyl fallout and outcome of pregnancy in Finland.
por: Auvinen, A, et al.
Publicado: (2001)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland
por: Leinonen, Maarit K, et al.
Publicado: (2012)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Prostate cancer screening: what can we learn from randomised trials?
por: Auvinen, Anssi
Publicado: (2018)

Breast cancer screening as public health policy in Finland.
por: Hakama, M., et al.
Publicado: (1991)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Serum ceruloplasmin and the risk of cancer in Finland.
por: Knekt, P., et al.
Publicado: (1992)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Prostate specific antigen for early detection of prostate cancer: longitudinal study
por: Holmström, Benny, et al.
Publicado: (2009)

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
por: Rannikko, Antti, et al.
Publicado: (2022)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

Psychological recovery and well-being of spouses of patients with prostate cancer 5 years after primary treatment in Finland: a follow-up survey
por: Lehto, Ulla-Sisko, et al.
Publicado: (2023)

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
por: Kitagawa, Yasuhide, et al.
Publicado: (2014)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design
por: Malila, Nea, et al.
Publicado: (2008)

Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland
por: Tikkinen, Kari A.O., et al.
Publicado: (2007)

Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population
por: Rajaei, Mohammad, et al.
Publicado: (2013)

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate
por: Kohestani, Kimia, et al.
Publicado: (2021)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening
por: Jen, Hsiao-Hsuan, et al.
Publicado: (2020)

Prostate-specific antigen-based screening: controversy and guidelines
por: Kim, Eric H, et al.
Publicado: (2015)

Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
por: Talvitie, Anna-Maija, et al.
Publicado: (2023)

Prostate-specific antigen in serum of women with breast cancer.
por: Giai, M., et al.
Publicado: (1995)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
por: Wald, N J, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_pibmgklr58f79tt40361m3ukdm